 |
 |
I saw my neuro and the Director of the Movement Disorder Program at the Cleo Roberts Center for Clinical Research today and learned “Dr. Moussa and colleagues are now planning a double-blind, placebo controlled phase 2 clinical trial testing nilotinib in patients with PD and other neurodegenerative diseases (including Alzheimer’s disease). The study is likely to begin in 2016.” “The phase 1 study received philanthropic funding and was supported by the Georgetown-Howard Universities Center for Clinical and Transitional Science. Dr. Charbel Moussa is an inventor on a Georgetown University patent application for use of nilotinib and other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases. Colleague Dr. Fernando Pagan has disclosed no relevant financial relationships.’ Director explained to me that because of patent, others cannot do trials without Moussa/Georgetown approval. He will see Moussa this month and relay my appeal for more trials, hopefully at the Barrow in Phoenix or the Cleo in Sun CIty. email Dr. Charbel Moussa at this site. you have to fill out form giving your email, his is not shown. I emailed him but am too tired to keep looking for snail mail address now. I think Tony Adler has it. http://contact.georgetown.edu/mail/ phone 1-202-687-7328 if you can speak Both neuros will keep me Informed, so we should know more soon. PS- I donated my brain to brain bank Ray Rayilyn Brown Past Director AZNPF Arizona Chapter National Parkinson Foundation ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn